Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
CEO Samarth Kulkarni reports the acquisition of stock options and restricted stock units in CRISPR Therapeutics.
Summary
- On March 14, 2025, CRISPR Therapeutics CEO Samarth Kulkarni was granted stock options for 110,000 common shares at an exercise price of $42.12.
- These options vest in 48 equal monthly installments starting April 14, 2025.
- Kulkarni also received 82,500 restricted stock units (RSUs) on the same date.
- These RSUs vest in four equal installments annually on March 14, 2026, 2027, 2028, and 2029.
- Following these transactions, Kulkarni directly owns 110,000 stock options and 82,500 RSUs.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The equity grants are a standard part of executive compensation and align the CEO's interests with shareholders. There are no immediate negative implications.
Positives
- The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders.
- The vesting schedules encourage long-term commitment and performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted equity.
Industry Context
Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives, aligning their interests with the long-term success of the company.
Comparison to Industry Standards
- Equity compensation packages for CEOs in the biotech industry typically include a mix of stock options and restricted stock units.
- The vesting schedules are fairly standard, with options vesting over four years and RSUs often vesting annually.
- Comparable companies like Intellia Therapeutics and Editas Medicine also utilize similar equity compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize the CEO to drive long-term value creation.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of stock option and RSU grant |
| 04/14/2025 | First vesting date for stock options |
| 03/14/2026 | First vesting date for RSUs |
| 03/14/2027 | Second vesting date for RSUs |
| 03/14/2028 | Third vesting date for RSUs |
| 03/14/2029 | Fourth vesting date for RSUs |
| 03/14/2035 | Expiration date for stock options |
| 03/18/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.